Search company, investor...
Genome Medical company logo

Genome Medical

genomemedical.com

Founded Year

2016

Stage

Series C | Alive

Total Raised

$120.41M

Last Raised

$60M | 1 yr ago

About Genome Medical

Genome Medical is a national telegenomics technology and services company bringing genomic medicine to everyday care. Through its nationwide network of genetic specialists and efficient genomic care delivery platform, it provides virtual genetic care for individuals and their families to improve health and well-being. The company also helps healthcare providers and their patients navigate the rapidly expanding field of genetics and utilize test results to understand the risk for disease, accelerate disease diagnosis, make informed treatment decisions and lower the cost of care.

Headquarters Location

701 Gateway Blvd. Suite 380

South San Francisco, California, 94080,

United States

877-688-0992

ESPs containing Genome Medical

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this market provide tests that help to determine the appropriate course of treatment for a given patient based on their genomic profile. Many solutions in this space also include a software portal that enables physicians to easily navigate the data and make decisions.

Genome Medical named as Highflier among 13 other companies, including Tempus, Caris Life Sciences, and Genomenon.

Compete with Genome Medical?

Ensure that your company and products are accurately represented on our platform.

Genome Medical's Products & Differentiators

    Genome Care Delivery platform

    The Genome Care Delivery digital health platform is the foundation of our virtual care services. It features a set of configurable “genomic insights as a service”, SaaS-type solutions, designed to augment existing services or create the foundation of new services and capabilities. Patient and provider tools help ensure informed, accurate decisions about preventive screening, diagnostic testing and results management to both improve outcomes and increase efficiency. Patients are guided through all aspects of their genetic health journey: engagement and education; risk assessment; genetic counseling, appropriate test recommendations; test ordering, authorization and logistical support; return of test results; and integration of results into ongoing health management.

Expert Collections containing Genome Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genome Medical is included in 9 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare

D

Digital Health 150

450 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

H

Health Monitoring & Diagnostics

2,530 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Hospital

198 items

Startups recreating how healthcare is delivered

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Latest Genome Medical News

FSHD Society Establishes TestFSHD, a Genetic Testing Program

Oct 24, 2022

The FSHD Society has launched a direct-to-patient clinical diagnostic genetic testing program for facioscapulohumeral muscular dystrophy (FSHD). Called TestFSHD , the program’s aim is to overcome critical barriers that patients currently face when trying to obtain genetic testing for the rare, debilitating muscle disorder. FSHD is one of the most common hereditary muscle diseases and is thought to affect nearly one million individuals worldwide. Because of widespread lack of access to diagnostic testing, the majority of those who have FSHD have not had their diagnosis confirmed genetically. The TestFSHD program ensures that eligible U.S.-based patients seeking a clinically approved genetic diagnosis of FSHD have a comprehensive and streamlined path to a genetic test. The program provides virtual genetic counseling, medical referrals, mobile blood-draws, and comprehensive FSHD1 and FSHD2 genetic testing. These services are provided by Genome Medical , a telemedicine company specializing in genetic counseling, with blood-draws by ExamOne phlebotomy service and genetic tests requisitioned from commercial diagnostic laboratories such as PerkinElmer Genomics and the University of Iowa Diagnostic Laboratories. Genome Medical counselors can also assist patients in filing claims with their health insurance. “Confirmation of FSHD by a clinically approved genetic test remains one of the primary barriers impacting rapid recruitment into clinical trials,” explains Jamshid Arjomand, PhD, Chief Science Officer at the FSHD Society. “The TestFSHD program provides patients with a solution to overcome barriers to clinical trial eligibility, which should help streamline the recruitment process in upcoming trials.” The lack of access to genetic testing had become an obstacle to progress because many treatments being developed for FSHD target the genetic cause of the condition. This means that patients must be genetically confirmed to have FSHD before they can enroll in clinical trials or, eventually, be eligible to receive such treatments. The Society noted that the low percentage of patients with genetically confirmed FSHD could undermine or slow down upcoming clinical trials. To build up a ‘trial-ready’ patient population, the FSHD Society analyzed the obstacles faced by patients, identified the partner companies to provide solutions, and established a process so each part of the system connected smoothly to the others. The program has clearly had its intended impact. “I was diagnosed with FSHD over 11 years ago,” said one individual. “I recently completed the free genetic testing that you offered, and I met with the genetic counselor yesterday…I came back with a positive blood test [for] FSHD Type 1. I am ready and willing to take part in any clinical trials as soon as I’m able.” The FSHD Society partnered with Arrowhead Pharmaceuticals, Avidity Biosciences, Dyne Therapeutics, Fulcrum Therapeutics and Pfizer to sponsor a pilot of TestFSHD, which made the testing free for the first 150 qualifying patients. “These partnerships demonstrate the enthusiasm of key stakeholders to collectively advance a trial-ready patient community in collaboration with the FSHD Society,” remarks Ken Khatava, Chief Growth Officer at the FSHD Society. The sponsored, free phase of the program will end on October 31, 2022, but TestFSHD will remain in place to make it easy for patients and families to obtain clinical genetic testing, with the cost reimbursed by their health insurance or covered out of pocket. “The extreme difficulty of getting genetic testing for FSHD has long been a pain point in the patient journey,” explains Arjomand. “We are thrilled that TestFSHD empowers patients to obtain affordable genetic testing for themselves.” [Source(s): FSHD Society, PRWeb]

Genome Medical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Genome Medical Rank

Genome Medical Frequently Asked Questions (FAQ)

  • When was Genome Medical founded?

    Genome Medical was founded in 2016.

  • Where is Genome Medical's headquarters?

    Genome Medical's headquarters is located at 701 Gateway Blvd., South San Francisco.

  • What is Genome Medical's latest funding round?

    Genome Medical's latest funding round is Series C.

  • How much did Genome Medical raise?

    Genome Medical raised a total of $120.41M.

  • Who are the investors of Genome Medical?

    Investors of Genome Medical include Canaan Partners, Illumina Ventures, Kaiser Permanente Ventures, HealthInvest Equity Partners, Perceptive Advisors and 17 more.

  • Who are Genome Medical's competitors?

    Competitors of Genome Medical include Helix and 4 more.

  • What products does Genome Medical offer?

    Genome Medical's products include Genome Care Delivery platform and 4 more.

  • Who are Genome Medical's customers?

    Customers of Genome Medical include Kaiser Permanente NW and Virtua Health.

Compare Genome Medical to Competitors

InformedDNA Logo
InformedDNA

InformedDNA provides genetic benefits management services intended to connect genetic counselors to patients. The company's services include clinical genetic counseling, genetic testing utilization management, genetic testing payment integrity, and expert genetics clinical trial support, enabling clients to access to the use of genetics in healthcare when required.

P
Prosper eDNA

Prosper eDNA increases accuracy and planning for insurance companies working in life, long-term care and annuities by making accurate lifespan predictions, and enabling personalized epigenetic (not genetic) monitoring.

Chronomics Logo
Chronomics

Chronomics is an AI-driven platform unlocking epigenetics for data-driven personalized healthcare. The web-based service gives individual insight into their changing state of health and wellbeing, empowering them with a tool for better living.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine-learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. The company was founded in 2015 and is based in Chicago, Illinois.

Akkure Logo
Akkure

Akkure Genomics offers a medical technology platform that aims at solving systemic problems in the clinical trials industry. The platform offers includes online self-assessment tools that match patient data to the most relevant clinical trials and remote consultations for remote consultations. It was formerly known as Akkure Genomics. The company was founded in 2019 and is based in Dublin, Ireland.

ORIG3N Logo
ORIG3N

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based upon Nobel Prize winning technology. This will replace the trial & error guess work of treating disease and enable longer, healthier lives.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.